Podcasts about Basket

Robert first came into recovery February 9, 1986 and met a group of people who would change his life. After a short relapse, Robert came back to recovery on April 25 of 1986 and has been clean and sober ever since. Robert's mission is to become more well and to encourage others along the way.Robert is also the host of The Recovery Guy Podcast and was also a panelist on the 12 part Reco12 series called the "Ask-it Basket".  He will be marking 40 years in the rooms of recovery in a couple of weeks.Reco12 is an open-to-all addictions and afflictions organization, dedicated to exploring the common threads of the differing manifestations of alcoholism; sharing tools, and offering hope from those walking a similar path. We gather from diverse backgrounds, faiths, and locations to learn and support one another. Our speakers come from various fellowships and experiences, demonstrating the universal principles of recovery.  Reco12 is not allied or affiliated with any specific 12 Step fellowship.Support Reco12's 12th Step Mission! Help provide powerful audio resources for addicts and their loved ones. Your contributions cover Zoom, podcasts, web hosting, and admin costs.Monthly Donations: Reco12 SupportOne-Time Donations: PayPal | Venmo: @Reco-Twelve | Patreon | WISEYour support makes a difference—thank you!Outro music is "Just Can't Do this On My Own" written by James Carrington, Thomas Barkmeijer and Paul Freeman and performed by James Carrington and used with full permission of James Carrington.  To learn more about this music and performer, please visit https://www.jamescarrington.net/ and https://m.facebook.com/jamescarringtonmusic Information on Noodle It Out with Nikki M Big Book Roundtable Informational Seeking and educating on how to donate to Reco12.Support the showPrivate Facebook GroupInstagram PageBecome a Reco12 Spearhead (Monthly Supporter)PatreonPayPalVenmo: @Reco-TwelveYouTube ChannelReco12 WebsiteEmail: reco12pod@gmail.com to join WhatsApp GroupReco12 Shares PodcastReco12 Shares Record a Share LinkReco12 Noodle It Out with Nikki M PodcastReco12 Big Book Roundtable Podcast

LeAnder Goldtooth is one of very few people his age keeping the art of Navajo basket weaving alive. At just 23 years old, he's become a master of the craft, harvesting his own sumac, reviving ancient patterns, and sharing his knowledge with the next generation. - Show Notes - • LeAnder Goldtooth on Instagram: www.instagram.com/ashkiiasaa.goldtooth/ Photo: LeAnder Goldtooth holds two baskets he's working on for an upcoming ceremony. Photo by Emily Arntsen/KZMU.

It is Giannis or bust for the Warriors future

Plusieurs débats au cœur de l'actualité, les Grandes gueules ont le choix, en débattre ou non : La star du basket Wemby "horrifiée" par l'actu à Minneapolis ; Soumission chimique : 18 mois ferme pour le sénateur Guerriau On recherche un consul général français au Groenland !

Programa de baloncesto NBA conducido por Gonzalo Vázquez y Andrés Monje gracias a Gigantes del Basket. ............................. MERCADO DE RIESGOS Los peligros de la urgencia y el gasto del futuro ............................. A escasas fechas del cierre de mercado El Reverso se detiene esta semana en el momento que viven las transacciones entre los equipos hoy día en la NBA. Con el apoyo del caso Giannis nos adentramos en las diversas estrategias que afrontan las franquicias, el cambio histórico en las dinámicas y precios, y el potencial peligro asociado a una mala gestión de traspasos. Programa ilustrativo para entender la doble cara de un mercado acuciante.

Programa de baloncesto NBA conducido por Gonzalo Vázquez y Andrés Monje gracias a Gigantes del Basket. ............................. MAZZULLA, CREDO O MUERTE El entrenador, el personaje y el poder de la fe ............................. Contra lo que parecía un año de transición los Celtics están firmando una gran temporada. Esta semana El Reverso se adentra en la valiosa labor de su principal artífice, el técnico Joe Mazzulla. Abordamos una vez más su inclasificable figura y la imposibilidad de separar al entrenador del personaje.

One of the most celebrated movies of all time, Silence of the Lambs (1991) redefined the psychological drama. From taking you into the mind of a serial criminal to enhancing the fear and tension of a criminal hunt, this movie defined how crime drama would be told. Let us know your thoughts by leaving a review.Also Play:Cinema Chain Game--------------------------------------------Subscribe, rate, and review:Apple Podcasts: Our Film FathersSpotify: Our Film FathersYouTube: Our Film Fathers---------------------------------------------Follow Us:Instagram: @ourfilmfathersTwitter / X: @ourfilmfathersEmail: ourfilmfathers@gmail.com

In today's episode we draft things that are high risk/low reward, taste test Sour Skittles Gummies, hint at a potential Bread Basket On Ice episode coming soon, answer lots of questions from the breadsticks, and more!! Be sure to tune in every Monday and Thursday for new episodes!

Programa de baloncesto NBA conducido por Gonzalo Vázquez y Andrés Monje gracias a Gigantes del Basket. ............................. ESPECIAL PREGUNTAS VIII Octava edición dedicada a los oyentes vía #ElReversoPreguntas ............................. El Reverso estrena el año con otro clásico: la octava edición dedicada a las preguntas de los oyentes. Un nutrido lote de cuestiones de actualidad e historia de la NBA, jugadores y leyendas, valoraciones, calendario futuro y posibilidades, recursos técnicos nuevos y perdidos, y parte de lo que nos habéis planteado a través del hashtag #ElReversoPreguntas que mantendremos siempre activo.

Listeners share why they love Market Basket and try to convince Ashlee to start shopping there. See omnystudio.com/listener for privacy information.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

With God's help and the power of the Holy Spirit, I will TAKERESPONSIBILITY for my life. Never again will I BLAME someone else for where I am. The BUCK STOPS with me.Genesis 1:27 “So God created mankind in his own image, in the image of God he created them; male and female he created them.”Genesis 1:28 “God blessed them and said to them, ‘Be fruitful and increase in number; fill the earth and subdue it. Rule over the fish in the sea and the birds in the sky and over every living creature that moves on the ground.'”Genesis 3:6 “When the woman saw that the fruit of the tree was good for food and pleasing to the eye, and also desirable for gaining wisdom, she took some and ate it. She also gave some to her husband, who was with her, and he ate it.”Genesis 3:11–13 “And he said, ‘Who told you that you were naked? Have you eaten from the tree that I commanded you not to eat from?' The man said, ‘The woman you put here with me—she gave me some fruit from the tree, and I ate it.' Then the Lord God said to the woman, ‘What is this you have done?' The woman said, ‘The serpent deceived me, and I ate.'”THE 3 PLACES WE DIRECT BLAME1. We like to blame GOD.2. We like to blame OTHER PEOPLE.3. We like to blame THE DEVIL.As long as we blame somebody else versus taking responsibility ourselves, we cannot make PEACE with our PAST or move FORWARD to a better FUTURE.1. Blame is the BASKET that carries your issues into the FUTURE.Sometimes YOU ARE to blame.2. Blaming FORFEITS your POWER to change.John 16:33 “I have told you these things, so that in me you may have peace. In this world you will have trouble. But take heart! I have overcome the world.”What do you need to TAKE RESPONSIBILITY for today?

Kat and Phoebe discuss last month's big viral article on the plight of the millennial white guy (and violently disagree)! Also: Kat confesses to being a diversity hire, and Phoebe vows to professionally wrestle any man who dares tread on the sacred turf of straightness studies. This is our free episode for January; if you enjoy it, please consider subscribing!LINKS:Jacob Savage, unlike Dan Savage, knows not where the men are: https://www.compactmag.com/article/the-lost-generation/Jacob Savage's previous disappearance-based essay: https://www.tabletmag.com/sections/news/articles/the-vanishingOliver Traldi doing straight men studies: https://thepointmag.com/criticism/the-masculine-mystique/ This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit femchaospod.substack.com/subscribe

Happy New Year! Which resolution did you choose; to lose weight, get outta debt, or get organized? Those are the three most common resolutions. But with any good goal you must have a way to execute an action plan otherwise you will have the same environment just different desires.  Tame the Toddler  Sometimes it feels like there is a toddler running around in our brain, right? It is constantly reminding us of future things you need to do. You are just trying to do a task like write an email but your brain is constantly bombarded with things you want to do as you look around your office or wherever you are. I got so tired of that, that I started to write everything down. Your Sunday Basket® comes with index cards for this purpose. I quiet my brain so I can be productive. As long as I follow through on Sundays, my brain will trust me that it's written down and it will get addressed. If not, it throws a tantrum and says "Since you lied, and didn't do it when you said you would, I'm going to bug you more often so you don't forget." Don't let that toddler control the narrative in your brain as you try to work through and complete tasks - just write it down.  Write It Down  I was talking to someone about mindfulness. To be clear I asked him how he defined mindfulness. It's basically being present with a person or activity. I thought, well I'm like 100% mindful. I know it sounds unrealistic but the theory goes that a person has a task thought and then makes a decision about it. But I have a thought, write it down, and carry on with what I was doing. When I get free time throughout the day, I decide if it can wait till Sunday. If it can wait it goes in the Basket for review on Sunday. And if not I place it in front of the Sunday Basket to address when I have time that day. This is where time and capacity come from! I offload my thoughts into my environment. Study after study confirms this is the most effective strategy to remember what you want to remember to do in the future - prospective memory.  If your goal is to change up the spaces in your home, you need a Sunday Basket® to hold all of the ideas you have for that project. How you intend to use the drawers, cabinets, or spaces. It's 10x's harder to try to complete that task on memory alone because your brain is trying to remember all the normal stuff and all the ideas you have for that space. I don't know about you but my brain is the worst note taker! The Sunday Basket® is a great keeper of the notes about the things I want to do, have, and be! The Sunday Basket® is Spanx for Your Kitchen Counter Clutter Let's talk about all the boxes or catch all containers you have in your house. At some point you got a call that company was coming to your house. In one swoop, you gathered everything from your kitchen counter, but did you go through it after your company left? This is why the Sunday Basket® is the solution for normal people trying to do #allthethings.  If your goal this year is to get organized, get out of debt, or lose weight, the system, the essential "office supply" you need is the Sunday Basket®. You shove all your kitchen counter clutter in it, you feel more organized already(get your environment to match your intention), and it looks good on your kitchen counter just like Spanx for our bodies. The Sunday Basket® is an organized way and holding all of your ideas on how you want to accomplish getting organized, getting out of debt, losing weight, or any other resolution you set for yourself this year. EPISODE RESOURCES: The Sunday Basket® Sign Up for the Organize 365® Newsletter  Did you enjoy this episode? Please leave a rating and review in your favorite podcast app. Share this episode with a friend and be sure to tag Organize 365® when you share on social media.  

Le duo Luka Doncic - Austin Reaves a-t-il un avenir à Los Angeles ? Les deux joueurs peuvent-ils cohabiter sur le long terme dans la même équipe ? Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Parmi nos prédictions de 2026, on imagine très bien les Spurs et Victor Wembanyama se hisser jusqu'en Finales de Conférence à l'Ouest. Et on vous explique pourquoi !Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Pour ce dernier numéro de l'année, on vous dévoile nos attentes (et un peu aussi nos prédictions) pour l'année NBA 2026 : de la suite de cet exercice jusqu'aux Playoffs à la prochaine free agency de l'été !Les Spurs et Victor Wembanyama en Finales de Conférence, le crash à venir des Lakers et le départ du duo Austin Reaves - LeBron James, les Knicks de retour en Finals, le départ de Milwaukee de Giannis Antetokounmpo et de New York pour Guerschon Yabusele, les Celtics favoris de la prochaine saison, l'arrivée de Trae Young aux Wolves... On a décidé de se mouiller !Avec Fred Weis et Nicolas Sarnak.Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Les Celtics sont meilleurs que prévus et c'est en grande partie grâce à Jaylen Brown. L'ailier de Boston s'est transcendé pour porter sa franchise de toujours pendant l'absence de Jayson Tatum. Le retour de celui-ci pourrait-il poser un problème de hiérarchie du côté du TD Garden ?Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Shedeur Sanders has shown that he can compete for the starting quarterback position next season, but should they be putting all their eggs in his basket?

La saison a démarré il y deux mois et il était donc temps de faire un point sur la course au MVP. Deux hommes se détachent grandement alors que derrière, Luka Doncic semble avoir un temps d'avance sur la troisième marche du podium. Et Victor Wembanyama alors ?Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Existe-t-il un problème LeBron James à Los Angeles ? Le King, plus aussi souverain en attaque, est devenu un élément difficile à gérer en défense pour J.J Redick. Et cela agace notre consultant Chris Singleton.Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Anthony Davis est de plus en plus proche de la sortie. Les Mavericks sont à l'écoute de toutes les offres et ce week-end, Atlanta et Golden State sont venus aux informations pour l'ancien ailier des Lakers...Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Une zone de turbulence commence pour les Californiens avec la blessure pour un mois d'Austin Reaves. Luka Doncic et LeBron James ont été ciblés par leur coach J.J Redick alors que les Lakers ne semblent pas être en mesure de viser le titre cette année.A Dallas, tout semble indiquer que Anthony Davis va partir. Ce week-end, les Hawks et les Warriors se sont invités à la table des rumeurs pour acquérir l'intérieur des Mavericks. Feront-ils "all in" sur AD ?Après deux mois de compétition, on fait le point sur la course au MVP. Et vous, vous êtes plutôt Nikola Jokic ou Shai Gilgeous-Alexander ?Avec Chris Singleton et Nicolas Sarnak.Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Is that a real A-bomb? Will Carol and Paraguy ever get along? Will the Zoshive portmanteau ever catch on?Nique is joined by Gus, Kevin, and Ursula K. Le Guin reader Meg for a discussion of the Pluribus season 1 finale.Join us on Discord - the server is Moon Show Podcast and the channel is Pluribus.

La tradición en el deporte estadounidense es radicalmente diferente al español. Mientras que en España hay un descanso por Navidad, en la NBA se disputa una de las jornadas más especiales del año. José Manuel Calderón analiza en El Larguero lo más destacado de estos días en el baloncesto estadounidense. "Es un día muy especial, muy de Basket. Es una tradición disfrutar del baloncesto en familia", explica un jugador que ha disputado catorce temporadas en la NBA.

En échec aux Knicks, Guerschon Yabusele a-t-il encore un avenir sous les ordres de Mike Brown ? Un trade serait-il envisageable dès la trade deadline et surtout, doit-il réfléchir à un retour en Europe ?Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Food insecurity is surging in Carver County—and it doesn't look the way you might think. In this powerful conversation, Bountiful Basket Executive Director Patti Sinykin reveals why demand has jumped 72% in just one year, who's really walking through their doors, and what it takes to serve 9,615 people annually with dignity and compassion.You'll discover:Why hunger exists in one of Minnesota's most prosperous countiesHow the "super shelf" grocery store model restores dignity to families in crisisThe real faces behind food insecurity—teachers, neighbors, families just like yoursWhy Bountiful Basket serves anyone who walks through their doors, no income requirementsHow 3,000 pounds of food goes out daily (and what that actually looks like)The community resource navigator helping families beyond just foodHow you can help—whether through volunteering, food drives, or donationsPatti shares heartbreaking and hopeful stories: the teacher who drove to another city so his students wouldn't see him, the woman who lived in Chaska 30 years before learning help existed, the family that went from stable to struggling in just one month.With locations in Chaska and Cologne, Bountiful Basket isn't just feeding people—they're building community, restoring hope, and proving that kindness matters.RESOURCES MENTIONED:Bountiful Basket Food Shelf: bountifulbasket.orgPhone: (952) 448-9117Chaska Location: 1951 Park Place BoulevardCologne Location: 125 Village ParkwayTOP NEEDS: Cereal, hearty soups, crackers, volunteers (especially in Cologne)Living in Carver County Podcast - Connecting friends, building community through conversations with the people who make Carver County the best place to live, work, and raise a family.Host: Greg Anderson, licensed real estate professional serving Chaska, Chanhassen, Victoria, Waconia, and Carver County since 1985.Subscribe for weekly conversations with local business owners, community leaders, educators, and changemakers.#CarverCounty #FoodInsecurity #CommunityService #Chaska #Chanhassen #Minnesota #Nonprofit #Volunteer #FoodShelf #LivingInCarverCounty

Selon les mensurations fournies par les équipes, la taille des joueurs en NBA stagne, voire régresse de un centimètre par rapport aux dernières saisons. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Les Lakers, les Warriors, les Timberwolves et les Pistons devraient fortement animer la trade deadline, fixée au 5 février prochain. Quels échanges pourraient changer la dynamique de ces quatre franchises ? On tente de répondre.Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Toujours en quête de renfort pour aider Giannis Antetokounmpo, les Bucks auraient dans leur viseur Zach LaVine. Mais est-ce un bon pari à tenter ?Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

US President Donald Trump used a series of social media posts to outline his views on inflation, interest rates, and Federal Reserve (Fed) leadership, emphasizing a strong preference for lower rates but potentially raising rates as well.Guest: Tim Warren, Host of Investing BrozInvesting Broz Youtube ➜ ‪‪  @TimWarrenTrades  Follow on Twitter ➜  @timsta6753   00:00 Intro00:50 2026 outlook02:20 Trump: "We can always raise rates"03:45 Basket of altcoins for 202606:00 Does Economic data matter anymore?07:20 Tom Lee: double digit growth next year?08:30 Early 2026 Bitcoin target12:00 Bitcoin holders selling for tax purposes?15:15 Fed independance debate16:15 Scott Bessent on tariffs17:20 Do people like tariffs?19:20 Trump admin. to start garnishing wages in January20:30 Anthony Pompliano on Bitcoin volatility24:40 Ethereum analysis27:00 Tim's 2026 Picks28:20 Outro#Crypto #Bitcoin #ethereum~Volatility NIGHTMARE Ahead?

Ce sera le BIG match des NBA Christmas Games : San Antonio et Oklahoma City se retrouvent jeudi soir à 20h30 pour un nouveau choc très alléchant. Victor Wembanyama et les Spurs peuvent-ils être l'arme ultime pour contrecarrer les plans du Thunder ?Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Les Lakers, les Warriors, les Timberwolves et les Pistons devraient fortement animer la trade deadline, fixée au 5 février prochain. Quels échanges pourraient changer la dynamique de ces trois franchises ? On tente de répondre.Zach LaVine est la dernière rumeur en date concernant les Bucks. L'arrière de Sacramento serait-il un bon complément à Giannis Antetokounmpo ?La grande soirée de Noël offrira un 25 décembre très alléchant : on fait la preview des cinq matchs !Avec Chris Singleton et Nicolas Sarnak.Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Here’s the latest Snow Plow silliness brought to you by Holden Afart, Mattchew, SirVern, Basket of Grapes, and Teen Wolf Jesus. Today we’re…

Programa de baloncesto NBA conducido por Gonzalo Vázquez y Andrés Monje gracias a Gigantes del Basket. ............................. CUENTOS DE NAVIDAD VIII Michael, crimen y castigo ¿Conoces a Scott Foster? Michael, crimen y castigo (y II) ............................. Como cada año por estas fechas El Reverso ofrece un capítulo muy especial, los Cuentos de Navidad. Protagonizan esta octava edición dos personajes, dos grandes historias y el oscuro revés de lo muchas veces contado: una versión no muy agradable de Michael Jordan, un clásico de estos especiales, y el lado más desconocido del polémico árbitro Scott Foster. Gonzalo y Andrés se adentran una vez más en el otro lado. Desde El Reverso os deseamos unas felices fiestas.

Retour sur la période compliquée traversée par les Warriors, englués dans le ventre mou de la Conférence Ouest. Steve Kerr est-il encore l'homme de la situation ? Un trade de Jonathan Kuminga peut-il relancer les Dubs ?Jacques Monclar, Rémi Reverchon, Mary Patrux, Xavier Vaution, Fred Weis et Chris Singleton décryptent l'actualité de la NBA dans le Podcast NBA Extra, présenté par Nicolas Sarnak et Baptiste Denis.En complément de l'émission lancée en 2012, beIN SPORTS a créé, avec ce podcast, un nouveau format pour revenir en profondeur sur la ligue nord-américaine de basketball. Chaque semaine, les membres de l'émission débattent autour de trois thèmes majeurs, qui font l'actualité de la NBA.Un podcast à retrouver aussi sur Youtube : https://tinyurl.com/y4sabkns Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

big deep dark YIN

durée : 00:20:25 - Cultures Monde - par : Julie Gacon, Mélanie Chalandon - En 2020 une photo de neuf joueurs de NBA originaires des Balkans, tous réunis autour d'une table, fait le tour du monde. Trente ans après les accords de Dayton et la fin de la guerre en Bosnie, le succès commun de ces joueurs interroge les possibilités de réconciliation dans une région très divisée. - réalisation : Vivian Lecuivre - invités : Nicolas Skopinski Journaliste indépendant

Classic Christmas Stories: Aunt Cyrilla's Christmas Basket by L.M. MontgomeryEmbrace the holiday spirit with Classic Christmas Stories! This episode features "Aunt Cyrilla's Christmas Basket" by L.M. Montgomery, a delightful tale of kindness and Christmas cheer, perfect for families and story lovers. Airing in December 2025, enjoy daily classics from Nov 27–Dec 25. Subscribe for more festive joy, visit our merch store for holiday gifts, or support us on Buy Me a Coffee!Keywords: Aunt Cyrilla's Christmas Basket audiobook, L.M. Montgomery, Christmas story podcast, family holiday tales, free audiobooks, classic Christmas stories, cozy holiday podcast, holiday giftsSend us a textSupport the showHelp keep the stories interruption free! https://buymeacoffee.com/jasonreadsclassics Merch Store Chamber of Classics Amazon Links Cozy Blankets: https://amzn.to/42EuiP2 Christmas Mugs: https://amzn.to/3WENatG All stories in this podcast are public domain works, read by Jason Hovde. No copyrighted material is used. Media & Interview Inquiries: truthtrekking@gmail.com...

Danica talks to Olis and Sam about when she was an active drinker how easy it was to forget the consequences of alcohol. Early on as a sober AA member she recalls noticing how others took their service commitments very seriously, and she decided to do the same thing. When faced with a dilemma, she got a suggestion from her sponsor to seek out the experience of other AA members and that helped her make a key decision. In the Ask-it-Basket a newcomer asks about sponsorship. We hear Listener Feedback from Emily and Lana. Jim shares about how he benefits from the Grapevine Archives.While we provide the podcast at no charge, we do have expenses. Grapevine is the only AA entity that does not accept direct contributions, so to support the AA Grapevine Podcast, please subscribe to Grapevine Magazine in print, online, or on the Grapevine app. You can also provide a subscription to someone in need through our "Carry the Message" program or purchase books or other items at aagrapevine.org/storeYou can email us at podcast@aagrapevine.org. To record an Ask-It-Basket question or a recovery-related joke, call 212-870-3418 or email a voice recording to podcast@aagrapevine.org

Programa de baloncesto NBA conducido por Gonzalo Vázquez y Andrés Monje gracias a Gigantes del Basket. ............................. LA ESTRELLA OSCURA Breve historia de una tiranía silenciosa ............................. Tras el polémico adiós a Chris Paul y un inicio de temporada desastroso, El Reverso aborda esta semana la dramática situación de Los Angeles Clippers remontando tiempo atrás. En pleno reinado de Steve Ballmer el programa se adentra en las siniestras interioridades de la organización desde la llegada de su gran apuesta, Kawhi Leonard. Nada de lo ocurrido estos últimos seis años puede explicarse sin él (y la temible figura de su tío Dennis).

Hablando Basket con Sonso Esta semana en GW5 Sports venimos con un invitado sumamente especial, ya que es nativo de la familia de GW5. Alex Alicea (Dile No Al Sonso) se da la vuelta a hablar del basket en Puerto Rico desde los juveniles a los profesionales. Hablamos del desarrollo de baloncelistas en la isla desde los clubes como Bucaplaa, los torneos escolares y torneos como Buzzer Beater. Luego también llegamos a hablar de los profesionales jugando en ligas como la BSN, la puertorriqueña y en el exterior. También tocamos el tema de la selección nacional y los problemas que enfrenta al momento. Hay talento de sobra, pero al estar tan regados jugando alrededor del mundo y con un calendario que conflige se les hace difícil estar presente en todo momento. Este episodio es traído a ustedes por Intervalos Fitness Studio. Para más información puedes ver el instagram @intervalosfitness o llamar al 787-378-7090. Grabado desde GW-Cinco Studio como parte de GW5 Network #tunuevatelevisión. Puedes ver toda la programación en www.gwcinco.com. síguenos en instagram @gw_cinco Patreon: patreon.com/bienabiertas patreon.com/gw5network patreon.com/hablandopop

Do you struggle to share your "big" emotions with God and others? Many of us are tempted to hide our feelings because we fear being "too much" or feel ashamed at some of the attitudes that lie underneath our hurts. Yet this keeps us from receiving the grace that all of our souls desperately need. Tune in for this episode of Soul Talks as Bill listens to Kristi with empathy and helps her see how her emotional honesty is a blessing to her relationship with God and those around her. You'll be equipped to integrate thinking with your feelings as you find safe people (like a spiritual director or soul friend) who can help you sort through your emotions as you become more healthy and whole like Jesus.Resources for this Episode:Attend a Soul Shepherding RetreatMeet with a Soul Shepherding Spiritual DirectorEarn a Certificate in Spiritual DirectionDonate to Support Soul Shepherding and Soul Talks

See omnystudio.com/listener for privacy information.

https://teachhoops.com/ Transition defense is arguably the most critical factor in defensive efficiency, yet it is often the most neglected aspect of practice. It starts with a non-negotiable mental shift: the moment the ball leaves a shooter's hand, the defensive possession begins. Great transition defense is not about speed; it is about floor balance and effort. A coach must enforce the "First Three Steps" rule, which mandates that the first three steps after a turnover or made basket are an all-out sprint toward the defensive paint. There is no time to mourn a missed layup, celebrate a made shot, or complain to an official. If a player is jogging or "backpedaling" (which is slower than running), they are actively hurting the team. The most effective teams designate a "safety" (usually the point guard) who rarely crashes the offensive glass, ensuring there is always one defender back to prevent the cherry-picking layup. Structurally, transition defense requires a strict hierarchy of priorities that every player must memorize. Priority number one is to protect the basket. The first defender back must run straight to the rim—not to the ball handler—to act as a "goalie" and deter the long pass. Priority number two is to stop the ball. Once the rim is protected, the next defender must pick up the ball handler aggressively to slow the dribble and force a pass. Priority number three is to match up. Defenders must communicate loudly by pointing and calling out "I got ball!" or "I got basket!" to avoid two players guarding the ball while a shooter runs free. The goal is to build a "wall" around the paint first, then fan out to shooters as the remaining defenders arrive. To truly improve transition defense, you must simulate the chaos of a turnover in practice. Standard 5-on-5 scrimmages often fail to replicate the urgency of a live-ball turnover because the game stops too frequently. Instead, utilize "Continuous Advantage/Disadvantage" drills (like 3-on-2, 2-on-1) where the defense must sprint back, communicate, and "build the wall" while outnumbered. Another effective method is "Change of Possession" drills, where the coach blows a whistle during an offensive set, throws the ball to the defense, and forces the offense to immediately sprint back to the other end. By drilling these scramble situations, players learn to organize themselves in seconds, turning what looks like a fast break opportunity for the opponent into a settled, half-court possession. Transition Defense, Basketball Defensive Strategy, Stopping the Fast Break, Sprint Back on Defense, Floor Balance, Defensive Safety, Protect the Basket, Stopping the Ball, Transition Defense Drills, Conversion Defense, Advantage Disadvantage Drills, Basketball Coaching Tips, Defensive Communication, Fast Break Defense, Basketball Transition Principles, 3 on 2 Drills, Basketball Hustle, Defensive Priorities, Reducing Fast Break Points, Coaching Transition Defense, Basketball Defensive Transition, Youth Basketball Defense, High School Basketball Strategy, Defensive Recovery, Basketball Scramble Drills Learn more about your ad choices. Visit podcastchoices.com/adchoices

Alex does a deep dive on French emperor Napoleon III and the lessons he teachers us. From his message of "Make France Great Again," to his many coup attempts, to finally getting elected the president of France on the backs of a massive Propaganda campaign. And once he became president he decided he wasn't going to be held back by term limits and made himself the emperor for life.  Subscribe for Mrs. Pearlmania Ghost Hunts - https://www.youtube.com/@Mrs.Pearlmania Support the show and get 30% off your Brooklyn Bedding order sitewide. Use promo code TOOMANY at https://www.brooklynbedding.com JOIN OUR COMMUNITY -